OXGENE
-
WuXi AppTec completes acquisition of Oxford-based OXGENE
This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
-
Oxford firms collaborate to scale up COVID-19 antigen production
Two Oxford businesses – OXGENE™ and The Native Antigen Company – have formed a strategic partnership to scale-up SARS-CoV-2 (COVID-19) antigen production.